Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Leber congenital amaurosis in which the cause of the disease is a mutation in the RDH12 gene.
Features include: Bone spicule pigmentation of the retina, Reduced visual acuity, Optic disc pallor, and Attenuation of retinal blood vessels and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Optic disc pallor, Attenuation of retinal blood vessels, Retinal dystrophy |
RDH12 function has not been fully characterized.
Leber congenital amaurosis 13 is associated with mutations in the RDH12 gene on chromosome 14.
Genetic testing for RDH12 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Leber congenital amaurosis 13 has been reported in the published literature.
No clinical trials have been registered for Leber congenital amaurosis 13.
41 publications have been identified in PubMed for Leber congenital amaurosis 13. Research spans Epidemiology / Natural History (39%), Basic Science / Preclinical (27%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 16 | 39% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:33 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Leber congenital amaurosis 13
1 |
Bone spicule pigmentation of the retina |
Laboratory research
11 |
27% |
Research summaries | 6 | 15% |
Testing and diagnosis research | 3 | 7% |
Patient case studies | 3 | 7% |
Clinical study results | 1 | 2% |
New treatment approaches | 1 | 2% |
Kadyshev VV (2026). [PMID: 41847811](https://pubmed.ncbi.nlm.nih.gov/41847811/). *Vestn Oftalmol*. [Epidemiology / Natural History]
Zhang ZH (2026). [PMID: 41759220](https://pubmed.ncbi.nlm.nih.gov/41759220/). *Stem Cell Res*. [Basic Science / Preclinical]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Pavlova P (2026). [PMID: 41683787](https://pubmed.ncbi.nlm.nih.gov/41683787/). *Int J Mol Sci*. [Basic Science / Preclinical]
Little DR (2026). [PMID: 41867838](https://pubmed.ncbi.nlm.nih.gov/41867838/). *bioRxiv*. [Diagnostic / Biomarker]
Yu SJ (2026). [PMID: 42000543](https://pubmed.ncbi.nlm.nih.gov/42000543/). *Stem Cell Res*. [Basic Science / Preclinical]
Gong X (2025). [PMID: 40232708](https://pubmed.ncbi.nlm.nih.gov/40232708/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Lee H (2025). [PMID: 39835736](https://pubmed.ncbi.nlm.nih.gov/39835736/). *Mol Genet Genomic Med*. [Case Report / Case Series]
Ameri H (2025). [PMID: 39930178](https://pubmed.ncbi.nlm.nih.gov/39930178/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Simoens D (2025). [PMID: 41140124](https://pubmed.ncbi.nlm.nih.gov/41140124/). *Cutan Ocul Toxicol*. [Review / Meta-Analysis]